Determination of EC95 of remifentanil for smooth emergence from sevoflurane anesthesia in patients undergoing trans-femoral cerebral angiography

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002691

Enrollment

Registered

2018-02-12

Start date

2018-02-12

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : All study participants will undergo general anesthesia using sevoflurane and remifentanil for the procedure. Sevoflurane is discontinued after completion of the procedure and a predetermined co

s method was used. The initial predetermined Ce of remifentanil TCI was 2.0ng/mL for the first patient because it is median value of EC50 and EC 95 according to previous stuides. The concentration cha

s method. If the patient did not cough during emergence, the extubation was defined as successful. Conversely, if the patient coughed at any point around the time of extubation, it was considered a fa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults undergoing TFCA because of cerebrovascular disease ( age from 20 to70 years ) ASA class I - III patients who agree to the clinical trial and signs written informed consent

Exclusion criteria

Exclusion criteria: - Symptoms or signs of increased intracranial pressure - uncontrolled hypertension - preoperative administration of an antitussive agent - patients with gastroesophageal reflux - allergic history with use of remifentanil or contraindication for remifentanil - patients with arrythmia or congestive heart failure (new York heart association heart failure grade 3,4) - Acute or chronic respiratory disease or patients who require ventilator care after Trans-femoral cerebral angiography (Bronchial asthma, chronic obstructive lung disease, upper respiratory infection within 2 weeks etc.) - severe obesity (BMI > 35 kg/m2) - severe obstructive sleep apnea - anticipated difficult airway - A person who does not recover consciousness 20 minutes after discontinuing sevoflurane administration (Consider delayed emergence and exclude the patient from trial) - Patients who are judged to be inadequate to participate in clinical trials at the discretion of the researcher - Patients who do not agree to participate in the study

Design outcomes

Primary

Measure	Time frame
prevention of cough	—

Secondary

Measure	Time frame
Mean arterial pressure (MAP);heart rate (HR);respiratory rate (RR);ETCO2 level;BIS score;emergence time;respiratory rate;sedation grade;aldrete score;side effect (pain, nausea/vomiting, shivering);duration of PACU stay	—

Countries

Korea, Republic of

Contacts

Public ContactJihye Kwon

Samsung Medical Center

kwonjh0828@hanmail.net+82-2-3410-0369

Outcome results